GlassScriptPhysician profile
Madison January
NPI 1194339200
$4,430.95
in general payments reported to CMS, 2019-2025
31 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $2,075 · 2023: $1,205 · 2024: $237 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $870.93 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $484.21 | 2021-2023 | |
| Progenics Pharmaceuticals, INC. | $452.59 | 2022-2024 | Pylarify |
| Axonics, INC. | $327.72 | 2022-2023 | Axonics |
| Astellas Pharma US INC | $288.57 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $287.79 | 2021-2023 | Provenge |
| Olympus America INC. | $184.98 | 2023 | Itind System |
| Endo Pharmaceuticals INC. | $159.95 | 2021-2022 | |
| Abbvie INC. | $153.68 | 2022-2023 | |
| Blue Earth Diagnostics | $140.37 | 2022-2023 | |
| Endo USA, INC. | $104.17 | 2025 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $99.96 | 2022-2023 | |
| Antares Pharma, INC. | $85.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.53 | 2023 | Lynparza |
| Myriad Genetic Laboratories, INC. | $72.79 | 2021-2023 | Prolaris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $72.07 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $67.13 | 2022 | |
| Urogen Pharma, INC. | $63.11 | 2022-2025 | Jelmyto |
| Urovant Sciences INC | $61.82 | 2021-2022 | |
| Boston Scientific Corporation | $51.48 | 2022-2023 | Ams 700 |
| Tolmar, INC. | $50.42 | 2023 | |
| Clarus Therapeutics INC. | $48.42 | 2021 | |
| Ambu INC. | $32.57 | 2023-2024 | |
| Acerus Pharmaceuticals Corporation | $29.98 | 2022 | |
| 180 Medical, INC. | $28.47 | 2023 | Gentlecath |
| Alnylam Pharmaceuticals INC. | $25.03 | 2021 | |
| Merck Sharp & Dohme LLC | $24.80 | 2022 | |
| Medtronic, INC. | $23.41 | 2023 | Interstim |
| Myovant Sciences INC. | $23.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.88 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison January listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.